US › Healthcare

Telix Pharmaceuticals Limited (TLX)

US · Healthcare · Biotechnology

$10.29+2.69%
Last close · 2026-08-04

Latest quarter · ended 2025-12-31

Revenue
$620.4M
Revenue YoY
+120.2%
Net profit
$-7.3M
Profit YoY
-137.1%
EPS
$0.04
EPS estimate
$0.08
Net margin
-1.2%

EPS came in at 0.04 against a street estimate of 0.08 — a miss of 48.1%.

Key statistics

Market cap
$3.35B
Forward P/E
250.0
P/B
8.07
Book value
$1.23
EPS (TTM)
$-0.02
52-week high
$14.27
52-week low
$6.28
50-day MA
$10.31
200-day MA
$9.30
Beta
0.63

Analyst view

Analysts rate Telix Pharmaceuticals Limited a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $20.78.

Shareholding

Institutions
0.86%

Largest institutional holders

FundStake
FMR Inc0.17%
Portolan Capital Management, LLC0.16%
Lazard Asset Management LLC0.09%
Manulife AIC Funds0.08%
Private Advisor Group, LLC0.05%
Integrated Wealth Concepts LLC0.05%
Hennion & Walsh Asset Management Inc0.04%
Raiffeisen Bank International AG0.04%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Telix Pharmaceuticals Limited — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.